IGF-1 LR3: Why Evading the Binding Proteins Changes Everything

Native insulin-like growth factor 1 is a 70-residue single-chain protein, structurally related to insulin, and it is the principal mediator of growth hormone's effects on peripheral tissue. IGF-1 LR3 is that protein with two changes. The 'R3' is a substitution: arginine replaces glutamate at position 3. The 'L' is length - a 13-residue extension on the N-terminus, giving 83 residues in total and a mass of roughly 9.1 kDa against native IGF-1's 7.6.

Both modifications serve the same end, which is reducing affinity for the IGF-binding proteins. Neither improves affinity for the IGF-1 receptor. Francis and colleagues drew exactly that distinction in 1992, and their title says it outright: what matters for enhanced potency in these analogues is binding-protein affinity, not receptor binding. This is the sentence that explains the entire compound.

PubChem does not resolve IGF-1 LR3 by name. Noreo's identity record therefore reports an approximate mass and residue count and omits formula, CAS and CID rather than publishing values that cannot be traced to a public database entry. For a recombinant protein of this size that limitation is compounded by the fact that identity properly depends on expression system, folding and post-translational state, none of which a formula would capture anyway.

IGF-1 does not circulate free. Six IGF-binding proteins compete for it, and in plasma the large majority is held in a ternary complex with IGFBP-3 and the acid-labile subunit. That arrangement is not incidental packaging - it extends IGF-1's half-life from minutes to hours, restricts access to the receptor, and makes the free fraction the physiologically active one. The binding proteins are the regulatory layer of the IGF system.

The same thing happens in a culture dish, which is where the practical motivation comes from. Cells secrete their own binding proteins into the medium, so native IGF-1 added to a well is partly sequestered before it reaches a receptor. The effective concentration is unknown and varies with cell type and confluence. An analogue that binding proteins bind poorly is far less subject to that sink, which makes it more consistent as a culture supplement - the reason IGF-1 LR3 became a standard reagent rather than a candidate drug.

Position 3 matters because of where it sits. The N-terminal region of IGF-1 forms part of the surface the binding proteins recognise, and glutamate at position 3 contributes a negative charge to that contact. Substituting arginine reverses the charge at that position and degrades the interaction. The related analogue des(1-3)IGF-1, which simply deletes the first three residues, shows the same effect by a cruder route - converging evidence that this small stretch of the N-terminus is what the binding proteins grip.

This detail is worth stating because it is almost always described wrongly. The 13-residue N-terminal extension is not a rationally designed pharmacological element. It is a remnant of how the protein was made.

King and colleagues expressed IGF-1 and its Glu3-substituted analogues in Escherichia coli as fusion proteins - a standard approach for producing a small disulfide-containing protein in bacteria, where a fusion partner improves yield and folding. When the construct was processed, a short peptide from the fusion partner remained attached to the N-terminus. Francis and colleagues, characterising the resulting molecules, found the extended forms were potent, and the extension further reduced binding-protein affinity rather than interfering.

So the extension was retained because it turned out to help, not because it was designed to. This is a common enough story in protein engineering, but it has a practical consequence: the extension sequence is a property of a particular expression strategy rather than a canonical feature, which is part of why identity verification for material sold under this name is harder than for a synthetic peptide with a defined sequence.

The in vivo literature on this analogue is mostly agricultural, and it is more interesting than that description suggests. Conlon and colleagues infused Long R3 IGF-I in guinea pigs in 1995 and reported organ growth stimulated while plasma IGF-I, IGF-II and binding-protein concentrations all fell. The analogue was not adding to the endogenous pool; it was suppressing it while acting in its place.

Dunaiski and colleagues took this further in pigs in 1997, with a result that ought to be quoted more often than it is: Long R3 IGF-I reduced growth, and reduced plasma growth hormone, IGFBP-3 and endogenous IGF-I. A more potent IGF-1 analogue producing less growth in a growing animal is a genuinely instructive finding. The mechanism it points to is feedback - IGF-1 signalling suppresses pituitary growth hormone output, so an analogue that reaches receptors efficiently also shuts down the endogenous axis efficiently, and the net effect on a whole organism need not be positive.

This is the crux of the difference between a cell-culture reagent and a systemic agent. In a dish, escaping the binding proteins is straightforwardly useful: more signal reaches the receptor, and there is no pituitary to respond. In an animal, the binding proteins are part of a regulated system with feedback loops, and disabling one layer of regulation produces compensatory changes in the others. The livestock literature reports the compensation directly.

The most recent work continues the pattern. Engel and colleagues administered Long R3 IGF-1 intranasally in a transgenic mouse model of Alzheimer's disease in 2025 and reported amyloid plaque remodelling in cerebral cortex without preservation of cognitive function. Thirty-plus years after the design papers, the frontier of this literature is still a rodent model with a mechanistic effect and no functional benefit.

Against native IGF-1, the difference is regulatory rather than functional. Both engage the IGF-1 receptor. Native IGF-1 exists in equilibrium with six binding proteins that determine how much of it is available and where; IGF-1 LR3 is designed to sit outside that equilibrium. Recombinant native IGF-1 has been developed as a human medicine under the name mecasermin for severe primary IGF-1 deficiency; the LR3 analogue has not been developed for human use at all and has no trial literature to appraise.

Against tesamorelin, the CJC-1295 compounds and ipamorelin, the difference is position in the axis. Those four act upstream - at the GHRH receptor or at GHS-R1a - and leave the pituitary to determine how much growth hormone is released, with feedback intact. IGF-1 LR3 is an analogue of the axis's terminal effector, modified specifically to evade its own regulatory layer. It is the opposite design philosophy: not stimulating the system, but circumventing it.

That framing also identifies the main gap. There is no published human pharmacokinetic, safety or efficacy data for IGF-1 LR3. The mechanistic literature is cell-culture; the in vivo literature is livestock and rodent, and includes results in which the analogue suppressed growth. IGF-1 receptor signalling is also mitogenic across many cell types, which is a well-characterised property rather than a speculative concern, and one that ought to inform how the absence of long-term data is read.